Updated for Tysbari 1Q10 sales as reported yesterday by BIIB:
In the first quarter global sales of Tysabri rose 28 percent to $292 million. As of the end of March, about 50,300 patients were on commercial and clinical Tysabri therapy worldwide. That compares with a figure of 48,800 patients as of the end of 2009.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.